Actieve functies van Hans-Gustaf Ljunggren
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
XNK Therapeutics AB
XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden. | Directeur/Bestuurslid | - | - |
Vycellix, Inc.
Vycellix, Inc. BiotechnologyHealth Technology Vycellix, Inc. is a life science company that specializes in the development of cell and gene-based therapies for various medical conditions such as hematology/oncology, autoimmunity/chronic inflammatory diseases, and organ/tissue transplantation. The private company is based in Tampa, FL. The company's platforms were discovered by scientists at the Karolinska Institutet in Sweden, which is known for its Nobel Assembly. Vycellix is headquartered in the United States, with scientific operations in Sweden. The company's mission is to develop and commercialize optimized, next-generation T cell and natural killer (NK) cell-based cancer therapies using its transformational Vy-UC universal cell technology. The CEO of the company is Evren Alici. | Directeur/Bestuurslid | - | - |
Corporate Officer/Principal | - | - | |
CellProtect Nordic Pharmaceuticals AB
CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The company was founded in 2012 and the CEO is Johan Liwing. | Directeur/Bestuurslid | - | - |
Loopbaan van Hans-Gustaf Ljunggren
Statistieken
Internationaal
Zweden | 3 |
Verenigde Staten | 2 |
Operationeel
Director/Board Member | 3 |
Corporate Officer/Principal | 1 |
Sectoraal
Health Technology | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
XNK Therapeutics AB
XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden. | Health Technology |
Vycellix, Inc.
Vycellix, Inc. BiotechnologyHealth Technology Vycellix, Inc. is a life science company that specializes in the development of cell and gene-based therapies for various medical conditions such as hematology/oncology, autoimmunity/chronic inflammatory diseases, and organ/tissue transplantation. The private company is based in Tampa, FL. The company's platforms were discovered by scientists at the Karolinska Institutet in Sweden, which is known for its Nobel Assembly. Vycellix is headquartered in the United States, with scientific operations in Sweden. The company's mission is to develop and commercialize optimized, next-generation T cell and natural killer (NK) cell-based cancer therapies using its transformational Vy-UC universal cell technology. The CEO of the company is Evren Alici. | Health Technology |
CellProtect Nordic Pharmaceuticals AB
CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The company was founded in 2012 and the CEO is Johan Liwing. | Health Technology |